54 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Reata’s Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application
Reata Pharmaceuticals Inc (NASDAQ:RETA) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome.…
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
8 Stocks Moving In Monday’s After-Hours Session
Gainers
Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share.
Reata Pharmaceuticals: Q2 Earnings Insights
Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 7.32% over the past year to ($1.32), which beat the estimate of ($2.08).
Reata Pharmaceuticals Q2 EPS $(1.32) Beats $(2.08) Estimate, Sales $2.22M Beat $1.25M Estimate
Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.08) by 36.54 percent. This is a 7.32 percent decrease over losses of $(1.23) per share
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.